Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

Tarceva

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Tarceva was produced by Roche and Astellas.

NICE reverses decision to restrict Tarceva access

NICE reverses decision to restrict Tarceva access NICE now appears to have backtracked on this potential new recommendation and has published guidance that does back the continued use of Tarceva for people with relapsed NSCLC. . ... A final decision on the use of Tarceva and Iressa is expected by

Global pancreatic cancer market to treble in value

Global pancreatic cancer market to treble in value We expect the Abraxane-gemcitabine regimen to win substantial patient share from all other major treatment options, including gemcitabine monotherapy, Tarceva-gemcitabine, and FOLFIRINOX regimens.”  . The market is also expected to

Boehringer cancer drug on course for NHS use in UK

Boehringer cancer drug on course for NHS use in UK Boehringer's drug will face two EGFR inhibitors already approved by NICE for NHS use: AstraZeneca and Teva's Iressa(gefitinib) and Roche's Tarceva(erlotinib).

Roche drug fails in lung cancer trial

Roche drug fails in lung cancer trial The METLung study looked at the effect of adding onartuzumab to Tarceva (erlotinib) as a second- or third-line therapy for patients with non-small cell lung cancer (NSCLC), but use ... of the drugs in combination was unable to demonstrate any "clinically

NICE reviews lung cancer drug guidance

NICE reviews lung cancer drug guidance Consults on availability of Roche's Tarceva and AZ's Iressa on NHS. ... The National Institute for Health and Care Excellence (NICE) has said it is reviewing the current guidance for two lung cancer drugs: Roche's Tarceva and AstraZeneca's Iressa.

[ Previous 5 results ] 7 8 9 10 11 12 13 14 15 16 [ Next 5 results ]

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Nobull Communications

Switched on Creative Communications. With an encyclopedic working knowledge of pharmaceutical industry rules and regulations, we create dynamic, intuitive and...

Latest intelligence

Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...
How will the Tories’ historic win shape the NHS?
Paul Midgley and Oli Hudson, of Wilmington Healthcare, explore the impact of December’s General Election result on 2020 and beyond...
CSR 'Christmas Spirit' 2019
OPEN Health champions CSR over Christmas by giving back to the community and increasing our activities and efforts...

Infographics